The favourable outcomes associated with high syndecan-4 levels in our study contrasts with other studies showing more incident MI [32], and poorer outcomes in high-risk individuals and other cardiovascular diseases [33–35] in patients with high serum levels. This evidence concerns the gene SDC4 and cardiovascular disorder.